about
A method to adjust for ascertainment bias in the evaluation of cancer registry data.New methods of handling cases of unknown age in cancer registry data.Familial risk of early and late onset cancer: nationwide prospective cohort studyGlobal cancer incidences are substantially under-estimated due to under-ascertainment in elderly cancer cases.Correction for under-ascertainment in cancer cases in the very elderly (aged 75+): external reference method.Iran cancer incidence should be corrected for under-ascertainment in cancer cases in the elderly (aged 65+).Miscarriage and risk of cardiovascular disease.C-reactive protein and seizures in focal epilepsy: a video-electroencephalographic study.Reproductive history and carotid intima-media thickness.The high prevalence of antiphospholipid antibodies in refractory focal epilepsy is related to recurrent seizures.Clinical predictors in patients with refractory epilepsy exposed to levetiracetam: a single-center study.High concentration of immunoglobulin A is associated with temporal lobe epilepsy.Interleukin-6 levels are increased in temporal lobe epilepsy but not in extra-temporal lobe epilepsy.Substantial under-estimation in cancer incidence estimates for developing countries due to under-ascertainment in elderly cancer cases.Systolic Hypertension in Pregnancy and Cardiovascular Mortality: A 44-Year Follow-up StudyDeterminants of unfavorable presentation of primary cutaneous melanomaPregnancy-related factors and the risk of isolated systolic hypertensionHigher risk of primary cancers after polycythaemia vera and vice versaClinical significance of glutamic acid decarboxylase antibodies in patients with epilepsyThe risk of contralateral breast cancer in daughters of women with and without breast cancerRisk-tailored starting age of breast cancer screening based on women's reproductive profile: A nationwide cohort study
P50
Q31111527-0FEABA67-6480-4330-9888-5B5F4EE463E2Q33361392-796C4551-C211-4E67-8DEE-ACDAB886692FQ36481037-96B0C71C-5D08-4828-B24E-1C432A69DCCFQ39969972-E439FB11-3ABB-4868-9B9B-516CA157E709Q40116347-F614DEA0-65EC-4231-B794-0A7935DC6400Q40140777-1591DFA2-B2A0-42B1-9648-288BABF47E5DQ43234568-C06E3FA7-493E-45E3-A5CD-2EF6CCDF0EC9Q43958205-DD06CC0A-B016-4E7D-8347-FA87DF1FF804Q43995190-1B1B1A04-0C3F-4314-89F7-7E4F1C5EBDCAQ44469864-6F2E1F7F-2B99-4376-B599-BFEF7C0A3213Q46849036-8D11BEE0-DF8D-4A38-B8EC-789ABBB03FAEQ48454764-09DB1313-D468-4A0F-A1A3-8339A0473005Q48719793-6BC96161-4679-4FF8-91A2-F1D7B18E245AQ53035026-7CCBCB3C-BC09-4E6D-9DE0-5EEFD7957849Q59760980-2F31BD24-E54E-47A8-B246-A8BC5ABA301BQ61968484-313BFB57-5D82-4E3E-BB24-48EB9093383FQ80204217-3EC956D4-BB65-4DC3-806B-F3DAB8EC570AQ83319280-1A3AED4C-8C62-48F3-9B72-1AB85912B357Q84689917-ED9834AA-66CC-48DF-822D-EF1D25B81219Q87205159-A388308F-AB15-4666-9B3A-7BF4E38C8FA2Q91421388-8824391B-71FE-4D6B-B15D-E7646ADCF0B2
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Elham Kharazmi
@en
Elham Kharazmi
@nl
type
label
Elham Kharazmi
@en
Elham Kharazmi
@nl
altLabel
Kharazmi E
@en
prefLabel
Elham Kharazmi
@en
Elham Kharazmi
@nl
P31
P496
0000-0003-4919-6641